This review of individual patient data compared primary coronary angioplasty (PTCA) with thrombolysis for acute myocardial infarction. Primary PTCA was more effective than thrombolytic therapy in reducing death, reinfarction, and stroke, with greatest absolute benefits for high risk patients. The conclusions are reliable, but treatment effects varied across the trials raising issues about how widely the results can be applied
analysis, completeness of follow-up data and concealment of outcome assessment. Authors sought clarification for differences between the analysis of the data provided and previously published results. The authors do not state explicitly how judgements of validity were made, in terms of who made the decisions or the criteria used.
Data extraction
The trial investigators provided IPD for their trial. The data requested included: the participants' baseline characteristics; inclusion criteria of the trial; number of participants (in total and in each treatment arm); thrombolytic agent used in the comparator arm; duration of symptoms; duration from symptom onset to PTCA or thrombolysis; duration from symptom onset to randomisation; reoccurrence of MI; total number of strokes; number of haemorrhagic strokes; duration from randomisation to fatal event; duration from randomisation to death or MI; number of participants who died over a follow-up period of up to 30 days; and the number who died over a follow-up period of 6 months.
The 6-month follow-up data missing for two studies were imputed on the basis of the combined event rates between 1 and 6 months' follow-up from the other nine studies. Additional imputed events were distributed into the treatment arms using the treatment effect observed in the shorter follow-up period of the two studies with missing data.
Methods of synthesis
How were the studies combined? For each outcome, a pooled relative risk (RR) with 95% confidence interval (CI) was calculated by intention-to-treat. Time to event data were analysed using regression methods. Regression methods were also used to categorise the participants as high, intermediate or low risk for subgroup analyses.
A sensitivity analysis was used to assess the effects of missing follow-up data.
Possible effects of publication bias were assessed by calculating the number of additional unpublished trials showing no benefit that would be needed to render the findings of the meta-analysis statistically non significant.
How were differences between studies investigated?
Differences in treatment effect between the studies were investigated by grouping studies in the meta-analyses according to the thrombolytic comparator used, the time from the start of thrombolytic therapy to the first balloon inflation, and the volume of PTCA procedures carried out at the study site annually.
Results of the review
IPD from 10 RCTs (n=2,725) were included; summary data from an additional study (n=90) for which IPD were not available were included in the analysis.
Mortality at 30 days was 4.3% for 1,348 participants randomised to PTCA and 6.9% for 1,377 participants assigned to thrombolytic therapy; there was a statistically-significant difference in favour of PTCA (RR 0.62, 95% CI: 0.44, 0.86, p=0.004). At 6 months the difference was still statistically significant, although imputing missing 6-month follow-up data for two studies in the analysis gave an overall difference that was not statistically significant (RR 0.73, 95% CI: 0.55, 0.98, p=0.04) . The combined death and reinfarction rates at 30 days were 7.0% for PTCA and 12.9% for thrombolysis, with a sustained effect at 6 months (RR 0.60, 95% CI: 0.48, 0.75, p<0.0001) . The risk of haemorrhagic stroke at 30 days was lower in the PTCA group (RR 0.06, 95% CI: 0.01, 0.5, p=0.009).
The median time to treatment was 47 minutes longer for patients treated with PTCA than for those treated with thrombolytic therapy (p<0.0001).
The rate of major in-hospital bleeding was similar in both treatment groups. The overall 30-day CABG rate was lower in the PTCA group (RR 0.74, 95% CI: 0.56, 0.98, p=0.04 ). There were insufficient data for analysis at the 6-month follow up.
The relative risk of death or nonfatal MI in the subgroups analysed was similar to the reduction overall. However, the
